Read by QxMD icon Read

EJNMMI Research

Sho Furuya, Osamu Manabe, Hiroshi Ohira, Kenji Hirata, Tadao Aikawa, Masanao Naya, Ichizo Tsujino, Kazuhiro Koyanagawa, Toshihisa Anzai, Noriko Oyama-Manabe, Tohru Shiga
BACKGROUND: Cardiac sarcoidosis (CS) is a rare but potentially life-threatening disease that causes conduction disturbance, systolic dysfunction, and, most notably, sudden cardiac death. 18 F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) plays important roles not only in diagnosing CS but also in evaluating the effects of anti-inflammatory therapy. A volume-based analysis of parameters measured by FDG PET, so-called cardiac metabolic volume (CMV), has emerged as a new assessment tool...
October 5, 2018: EJNMMI Research
Antoine Verger, Eric Malbos, Emmanuelle Reynaud, Pierre Mallet, Daniel Mestre, Jean-Marie Pergandi, Stéphanie Khalfa, Eric Guedj
BACKGROUND: The aim of this pilot study is to investigate the impact of virtual reality exposure therapy (VRET) on brain metabolism and connectivity. Eighteen patients with acrophobia were assessed by an 18 F-FDG PET scan sensitized by virtual exposure before treatment, and nine of them were assessed again after eight sessions of VRET. Statistical Parametric Mapping was used to study the correlations between metabolism and pretherapeutic clinical scores and to compare metabolism before and after VRET (p voxel < 0...
October 1, 2018: EJNMMI Research
Fayçal Ben Bouallègue, Denis Mariano-Goulart, Denis Agostini, Alain Manrique
BACKGROUND: We investigated the feasibility of left ventricular (LV) and right ventricular (RV) volume and function estimation using a first-pass gated 15 O-water PET. This prospective study included 19 patients addressed for myocardial perfusion reserve assessment using 15 O-water PET. PET data were acquired at rest and after regadenoson stress, and gated first-pass images were reconstructed over the time range corresponding to tracer first-pass through the cardiac cavities and post-processed using TomPool software; LV and RV were segmented using a semi-automated 4D immersion algorithm...
September 17, 2018: EJNMMI Research
Lena Vomacka, Marcus Unterrainer, Adrien Holzgreve, Erik Mille, Astrid Gosewisch, Julia Brosch, Sibylle Ziegler, Bogdana Suchorska, Friedrich-Wilhelm Kreth, Jörg-Christian Tonn, Peter Bartenstein, Nathalie Lisa Albert, Guido Böning
BACKGROUND: Glioma grading with dynamic 18 F-FET PET (0-40 min p.i.) is typically performed by analysing the mean time-activity curve of the entire tumour or a suspicious area within a heterogeneous tumour. This work aimed to ensure a reader-independent glioma characterisation and identification of aggressive sub-volumes by performing a voxel-based analysis with diagnostically relevant kinetic and static 18 F-FET PET parameters. One hundred sixty-two patients with a newly diagnosed glioma classified according to histologic and molecular genetic properties were evaluated...
September 10, 2018: EJNMMI Research
Tibor Vag, Katja Steiger, Andreas Rossmann, Ulrich Keller, Aurelia Noske, Peter Herhaus, Johannes Ettl, Markus Niemeyer, Hans-Jürgen Wester, Markus Schwaiger
BACKGROUND: CXCR4 is a chemokine receptor frequently overexpressed in invasive breast cancer that has been shown to play a major role in signaling pathways involved in metastasis. The aim of this retrospective analysis was to assess the diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer using the recently introduced CXCR4-targeted PET probe 68 Ga-Pentixafor. RESULTS: Thirteen patients with first diagnosis of breast cancer, four patients with recurrent disease after primary breast cancer, and one patient with axillary lymph node metastasis of unknown primary underwent CXCR4-targeted PET imaging using 68 Ga-Pentixafor...
September 6, 2018: EJNMMI Research
Erica Silvestri, Valentina Scolozzi, Gaia Rizzo, Luca Indovina, Marco Castellaro, Maria Vittoria Mattoli, Paolo Graziano, Giuseppe Cardillo, Alessandra Bertoldo, Maria Lucia Calcagni
BACKGROUND: The validation of the most appropriate compartmental model that describes the kinetics of a specific tracer within a specific tissue is mandatory before estimating quantitative parameters, since the behaviour of a tracer can be different among organs and diseases, as well as between primary tumours and metastases. The aims of our study were to assess which compartmental model better describes the kinetics of 18 F-Fluorodeoxygluxose(18 F-FDG) in primary lung cancers and in metastatic lymph nodes; to evaluate whether quantitative parameters, estimated using different innovative technologies, are different between lung cancers and lymph nodes; and to evaluate the intra-tumour inhomogeneity...
August 29, 2018: EJNMMI Research
Daphne Merel Valerie Huizing, Berlinda Jantina de Wit-van der Veen, Marcel Verheij, Marcellus Petrus Maria Stokkel
BACKGROUND: The main challenge for systemic radiation therapy using radiopharmaceuticals (SRT) is to optimise the dose delivered to the tumour, while minimising normal tissue irradiation. Dosimetry could help to increase therapy response and decrease toxicity after SRT by individual treatment planning. Peptide receptor radionuclide therapy (PRRT) is an accepted SRT treatment option for irresectable and metastatic neuroendocrine tumours (NET). However, dosimetry in PRRT is not routinely performed, mainly due to the lack of evidence in literature and clinical implementation difficulties...
August 29, 2018: EJNMMI Research
Christian Brand, Ahmad Sadique, Jacob L Houghton, Kishore Gangangari, Jose F Ponte, Jason S Lewis, Naga Vara Kishore Pillarsetty, Jason A Konner, Thomas Reiner
BACKGROUND: The folate receptor α (FRα)-targeting antibody-drug conjugate (ADC), IMGN853, shows great antitumor activity against FRα-expressing tumors in vivo, but patient selection and consequently therapy outcome are based on immunohistochemistry. The aim of this study is to develop an antibody-derived immuno-PET imaging agent strategy for targeting FRα in ovarian cancer as a predictor of treatment success. METHODS: We developed [89 Zr]Zr-DFO-M9346A, a humanized antibody-based radiotracer targeting tumor-associated FRα in the preclinical setting...
August 28, 2018: EJNMMI Research
Elisabetta De Bernardi, Alessandro Buda, Luca Guerra, Debora Vicini, Federica Elisei, Claudio Landoni, Robert Fruscio, Cristina Messa, Cinzia Crivellaro
BACKGROUND: A radiomic approach was applied in 18F-FDG PET endometrial cancer, to investigate if imaging features computed on the primary tumour could improve sensitivity in nodal metastases detection. One hundred fifteen women with histologically proven endometrial cancer who underwent preoperative 18F-FDG PET/CT were retrospectively considered. SUV, MTV, TLG, geometrical shape, histograms and texture features were computed inside tumour contours. On a first group of 86 patients (DB1), univariate association with LN metastases was computed by Mann-Whitney test and a neural network multivariate model was developed...
August 22, 2018: EJNMMI Research
Sofie M Adriaanse, Tim C de Wit, Mette Stam, Eline Verwer, Kora M de Bruin, Jan Booij
The InSPira HD system, a novel brain-dedicated SPECT scanner, allows for imaging with a high spatial resolution. Here, we tested whether this scanner can be used to image the dopamine transporter adequately. Therefore, striatal phantom and patient data acquired on the InSPira were compared head-to-head with the well-validated brain-dedicated NeuroFocus system. A striatal phantom filled with [123I] and 14 subjects (after [123I]FP-CIT injection) were scanned on both systems. [123I]FP-CIT SPECT scans were visually assessed...
August 22, 2018: EJNMMI Research
Martina Wirtz, Alexander Schmidt, Margret Schottelius, Stephanie Robu, Thomas Günther, Markus Schwaiger, Hans-Jürgen Wester
BACKGROUND: Several radiolabeled prostate-specific membrane antigen (PSMA) inhibitors based on the lysine-urea-glutamate (KuE) motif as the pharmacophore proved to be suitable tools for PET/SPECT imaging of the PSMA expression in prostate cancer patients. PSMA I&T, a theranostic tracer developed in our group, was optimized through alteration of the peptidic structure in order to increase the affinity to PSMA and internalization in PSMA-expressing tumor cells. However, further structural modifications held promise to improve the pharmacokinetic profile...
August 22, 2018: EJNMMI Research
Yuji Tsutsui, Hiromitsu Daisaki, Go Akamatsu, Takuro Umeda, Matsuyoshi Ogawa, Hironori Kajiwara, Shigeto Kawase, Minoru Sakurai, Hiroyuki Nishida, Keiichi Magota, Kazuaki Mori, Masayuki Sasaki
BACKGROUND: Recent developments in hardware and software for PET technologies have resulted in wide variations in basic performance. Multicentre studies require a standard imaging protocol and SUV harmonization to reduce inter- and intra-scanner variability in the SUV. The Japanese standardised uptake value (SUV) Harmonization Technology (J-Hart) study aimed to determine the applicability of vendor-neutral software on the SUV derived from positron emission tomography (PET) images. The effects of SUV harmonization were evaluated based on the reproducibility of several scanners and the repeatability of an individual scanner...
August 20, 2018: EJNMMI Research
Mayu Tomita, Hironobu Yasui, Kei Higashikawa, Kohei Nakajima, Hideo Takakura, Tohru Shiga, Yuji Kuge, Mikako Ogawa
BACKGROUND: Programmed cell death 1 (PD-1) inhibitors act as immune checkpoint inhibitors and are more effective for improving survival time with less toxicity as compared with conventional chemotherapies. In anti PD-1 therapy, it is important to evaluate metabolism in the cancer microenvironment, as this helps to clarify the pathological conditions. Herein, we investigate the early effects of PD-1 therapy on 2-deoxy-2-[18 F]fluoro-D-glucose ([18 F]FDG) uptake in vivo, focusing on cell distribution and glycolysis in both cancer and immune cells...
August 16, 2018: EJNMMI Research
Dorra Amor, Sébastien Goutal, Solène Marie, Fabien Caillé, Martin Bauer, Oliver Langer, Sylvain Auvity, Nicolas Tournier
BACKGROUND: Erlotinib is an epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitor approved for treatment of non-small cell lung cancer. The wide inter-individual pharmacokinetic (PK) variability of erlotinib may impact treatment outcome and/or toxicity. Recent in vivo studies reported a nonlinear uptake transport of erlotinib into the liver, suggesting carrier-mediated system(s) to mediate its hepatobiliary clearance. Erlotinib has been identified in vitro as a substrate of organic anion-transporting polypeptide (OATP) transporters which expression does not restrict to hepatocytes and may impact the tissue uptake of erlotinib in vivo...
August 16, 2018: EJNMMI Research
Stefanie Pektor, Lina Hilscher, Kerstin C Walzer, Isabelle Miederer, Nicole Bausbacher, Carmen Loquai, Mathias Schreckenberger, Ugur Sahin, Mustafa Diken, Matthias Miederer
BACKGROUND: [18 F]Fluoro-2-deoxy-2-D-glucose positron emission tomography (FDG-PET) is commonly used in the clinic for diagnosis of cancer and for follow-up of therapy outcome. Additional to the well-established value in tumor imaging, it bears potential to depict immune processes in modern immunotherapies. T cells enhance their glucose consumption upon activation and are crucial effectors for the success of such novel therapies. In this study, we analyzed the T cell immunity in spleen after antigen-specific stimulation of T cells via highly innovative RNA-based vaccines using FDG-PET/MRI...
August 15, 2018: EJNMMI Research
Emma E Wolters, Sandeep S V Golla, Tessa Timmers, Rik Ossenkoppele, Chris W J van der Weijden, Philip Scheltens, Lothar Schwarte, Robert C Schuit, Albert D Windhorst, Frederik Barkhof, Maqsood Yaqub, Adriaan A Lammertsma, Ronald Boellaard, Bart N M van Berckel
BACKGROUND: Off-target binding in the choroid plexus (CP) may cause spill-in of the tau PET tracer [18 F] flortaucipir into the adjacent hippocampus region. The impact of this spill-in on hippocampal uptake was assessed using a novel partial volume correction method (PVC). METHODS: PVC was performed on 20 [18 F] flortaucipir dynamic PET scans (10 probable AD and 10 controls). Volumes of interest (VOIs) were defined for both hippocampus and CP. The correlation between hippocampal and CP distribution volume (VT ), with and without PVC, was determined...
August 15, 2018: EJNMMI Research
Jakub Šimeček, Petr Hermann, Christof Seidl, Frank Bruchertseifer, Alfred Morgenstern, Hans-Jürgen Wester, Johannes Notni
BACKGROUND: The recently growing interest in targeted alpha-therapy (TAT) calls for improvement of the labelling chemistry of the corresponding radionuclides. 213 BiIII is a short-lived alpha emitter which emits only one alpha particle in its decay chain. Hence, it might be safer in application than other respective nuclides, such as 223 Ra or 225 Ac, because no alpha-emitting daughters are released upon recoil. We investigated cyclen derivatives with phosphorus-containing pendant arms regarding their suitability for 213 Bi labelling...
August 8, 2018: EJNMMI Research
Sarah Schumann, Uta Eberlein, Jessica Müller, Harry Scherthan, Michael Lassmann
BACKGROUND: Irradiation with α-particles creates densely packed damage tracks along particle trajectories in exposed cells, including complex DNA damage and closely spaced double-strand breaks (DSBs) in hit nuclei. Here, we investigated the correlation of the absorbed dose to the blood and the number of α-induced DNA damage tracks elicited in human blood leukocytes after ex-vivo in-solution exposure with Ra-224. The aim was to compare the data to previously published data on Ra-223 and to investigate differences in DNA damage induction between the two radium isotopes...
August 6, 2018: EJNMMI Research
Astrid Gosewisch, Andreas Delker, Sebastian Tattenberg, Harun Ilhan, Andrei Todica, Julia Brosch, Lena Vomacka, Anika Brunegraf, Franz Josef Gildehaus, Sibylle Ziegler, Peter Bartenstein, Guido Böning
BACKGROUND: The bone marrow (BM) is a main organ at risk in Lu-177-PSMA-617 therapy of prostate cancer and Lu-177-Octreotate therapy of neuroendocrine tumours. BM dosimetry is challenging and time-consuming, as different sequential quantitative measurements must be combined. The BM absorbed dose from the remainder of the body (ROB) can be determined from sequential whole-body planar (WB-P) imaging, while quantitative Lu-177-SPECT allows for more robust tumour and organ absorbed doses...
August 3, 2018: EJNMMI Research
Keelara Abiraj, Samer Ursillo, Maria Luisa Tamma, Svetlana N Rylova, Beatrice Waser, Edwin C Constable, Melpomeni Fani, Guillaume P Nicolas, Jean Claude Reubi, Helmut R Maecke
BACKGROUND: Somatostatin receptor targeting radiopeptides are successfully being used to image, stage, and monitor patients with neuroendocrine tumours. They are exclusively agonists that internalise upon binding to the relevant receptor. According to recent reports, antagonists may be preferable to agonists. To date, 99m Tc-labelled somatostatin receptor antagonists have attracted little attention. Here, we report on a new somatostatin receptor subtype 2 (sst2) antagonist, SS-01 (p-Cl-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Thr-Cys)D-Tyr-NH2 ), with the aim of developing 99m Tc-labelled ligands for SPECT/CT imaging...
August 2, 2018: EJNMMI Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"